NEW YORK (GenomeWeb) – Researchers in Germany have found that a PCR-based method to detect methylation of a biomarker gene found in biopsy samples could anticipate prostate cancer recurrence and be used to prevent unneeded radical treatments. 

The assay detects methylation of the PITX2 gene, and was shown to discriminate between cancer and non-cancerous tissue as well as to predict biochemical recurrence after surgery. Importantly, the researchers also found the assay was sensitive enough that it could yield results even with small core needle biopsy samples.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Chan Zuckerberg Initiative is investing in Cold Spring Harbor Laboratory's BioRxiv.

A study appearing in PLOS One finds that shortened consent forms don't affect clinical trial participants' understanding of the study.

The National Security Agency monitored signal intelligence for signs of "nefarious" genetic engineering projects, Gizmodo reports.

In Nature this week: barley genome sequenced, method for genotyping and phasing short tandem repeats, and more.